Excellence and Innovation in patients care

www.recherche.unicancer.fr/en
The health crisis has demonstrated the need for an agile health system and a supportive environment for research and innovation.

Although the development of science, research and new technologies now makes it possible to better detect, treat and live with cancer, it remains the leading cause of death in France.

This is why cancer research is one of the foundations of the Unicancer network’s ambition, which is to do everything possible to provide patients with ever earlier detection and ever more innovative and personalised treatments.

Unicancer is more than 22,000 highly qualified women and men, united, committed and driven by a common and ambitious objective: to cure cancer.
**Publications in scientific journals**

- **3** Poles
  - Clinical Research
  - Translational Research
  - Health Data Research
- **10** Expert groups
  - 6 of which are accredited by INCa
- **109** ongoing clinical trials
  - For the Unicancer R&D department
- **60** Publications
- **20,000** Patients
  - included in Unicancer R&D sponsored-clinical trials of which 16,700 in MyPeBS

**GCS’ UNICANCER RESEARCH**

As the leading academic sponsor of clinical trials in oncology in Europe, Unicancer plays a leading role in cancer research.

Driven by strong values and ambitions, we have always defended the key levers of our strategy:
- **Intensify** prevention and screening
- **Improve** the quality of life of patients
- **Develop** artificial intelligence and data science
- **Increase** research programmes in cancers with an unfavourable prognosis

**RESEARCH IN THE UNICANCER NETWORK**

The Unicancer Research Network brings together the 18 FCCCs, two affiliated members and the Research Department of the Federation.

As major player in cancer research in France and internationally, Unicancer benefits from the strength of a dynamic, mobilised and pioneering network.

**Active clinical trials sponsored by the Unicancer network**

- **104** New trials
- **630** Active clinical trials

**Patients included in Unicancer R&D sponsored-clinical trials of which 16,700 in MyPeBS**

**GCS** : Groupement de Coopération Sanitaire

*(2021 figures)*
INTERNATIONAL: A FORWARD-LOOKING PRIORITY

Unicancer teams initiate and maintain collaborations with research actors at the international level. Unicancer is the local representative of the EORTC in France since 2009. In this way, we contribute to changing practices and promoting French excellence outside France.

This European grouping for the benefit of prostate cancer research has the ambition to conduct comparative trials in Europe to evaluate new treatments. By filling the "numerical gap" in phase III clinical trials, they are making a significant contribution to research and best practice in the treatment of genitourinary cancer. Many results have already been presented at conferences such as ESMO and ASCO.

UNICANCER OPENS ITS DATA TO RESEARCH

In order to accelerate the development of knowledge in oncology and to increase the interfaces between basic and clinical research (translational research), Unicancer Research provides researchers and clinicians from all institutions with access to data for their projects of interest.

In addition, the numerous ancillary research studies carried out in conjunction with clinical trials have enabled Unicancer to build up a collection of biological samples that can be associated with clinical data and thus allow reuse for research purposes, while respecting the current regulations.
FOCUS ON FLAGSHIP HEALTH DATA PROGRAMMES

ESMÉ is a unique real-life data collection and analysis system that centralises data on the management of patients with breast, lung and ovarian cancer in France.

is the first French reference platform developed to accelerate the production and exploitation of quality real-life data. As true drug observatory, ODH should make it possible to characterise the use of therapeutic innovations in oncology.

is a research infrastructure supported by future investment programmes dedicated to promoting and facilitating the integration of social and human sciences in cancer research, by pooling resources and skills.

is a study that aims to identify the long-term toxic effects of breast cancer treatments in order to improve the quality of life of women during and after cancer.

is an international study coordinated by Unicancer, funded by the European Union, evaluating a new breast cancer screening strategy based on each woman’s individual risk of developing the disease. A total of 85,000 volunteer women aged between 40 and 70 who have never had breast cancer are expected to participate in the recruiting countries: France, Italy, Israel, Belgium, UK, Spain.

www.mypebs.eu

THE PATIENT AT THE HEART OF OUR ACTIONS
We maintain close and lasting partnerships with the Ligue contre le cancer and the Fondation ARC, two non-profit organisations working for cancer research.
ACCELERATE RESEARCH AGAINST CANCER.
IMPROVE DIAGNOSTIC AND THERAPEUTIC METHODS.